{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:36:41Z","timestamp":1783741001094,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82470572"],"award-info":[{"award-number":["82470572"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"DOI":"10.1186\/s12887-025-05886-0","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T01:06:14Z","timestamp":1751850374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Liraglutide use in pediatric type 2 familial partial lipodystrophy caused by LMNA mutation: a case report"],"prefix":"10.1186","volume":"25","author":[{"given":"Youran","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuhen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"issue":"12","key":"5886_CR1","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1210\/jc.2016-2466","volume":"101","author":"RJ Brown","year":"2016","unstructured":"Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, Mungai L, Oral EA, Patni N, Rother KI, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016;101(12):4500\u201311.","journal-title":"J Clin Endocrinol Metab"},{"key":"5886_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cells12050725","author":"A Fernandez-Pombo","year":"2023","unstructured":"Fernandez-Pombo A, Diaz-Lopez EJ, Castro AI, Sanchez-Iglesias S, Cobelo-Gomez S, Prado-Mora\u00f1a T, Araujo-Vilar D. Clinical spectrum of LMNA-associated type 2 familial partial lipodystrophy: a systematic review. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12050725.","journal-title":"Cells"},{"issue":"1","key":"5886_CR3","first-page":"59","volume":"86","author":"A Garg","year":"2001","unstructured":"Garg A, Vinaitheerthan M, Weatherall PT, Bowcock AM. Phenotypic heterogeneity in patients with familial partial lipodystrophy (dunnigan variety) related to the site of missense mutations in lamin A\/C gene. J Clin Endocrinol Metab. 2001;86(1):59\u201365.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"5886_CR4","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/cen.14806","volume":"97","author":"ZX Zhong","year":"2022","unstructured":"Zhong ZX, Harris J, Wilber E, Gorman S, Savage DB, O\u2019Rahilly S, Stears A, Williams RM. Describing the natural history of clinical, biochemical and radiological outcomes of children with Familial partial lipodystrophy type 2 (FPLD2) from the united kingdom: A retrospective case series. Clin Endocrinol (Oxf). 2022;97(6):755\u201362.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"5886_CR5","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jacl.2021.07.004","volume":"15","author":"J Lazarte","year":"2021","unstructured":"Lazarte J, Wang J, McIntyre AD, Hegele RA. Prevalence of severe hypertriglyceridemia and pancreatitis in familial partial lipodystrophy type 2. J Clin Lipidol. 2021;15(5):653\u20137.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"5886_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/ng0398-292","volume":"18","author":"JM Peters","year":"1998","unstructured":"Peters JM, Barnes R, Bennett L, Gitomer WM, Bowcock AM, Garg A. Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22. Nat Genet. 1998;18(3):292\u20135.","journal-title":"Nat Genet"},{"issue":"17","key":"5886_CR7","doi-asserted-by":"publisher","first-page":"6450","DOI":"10.1073\/pnas.83.17.6450","volume":"83","author":"DZ Fisher","year":"1986","unstructured":"Fisher DZ, Chaudhary N, Blobel G. cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins. Proc Natl Acad Sci U S A. 1986;83(17):6450\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5886_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1399-0004.2005.00447.x","volume":"68","author":"R Hegele","year":"2005","unstructured":"Hegele R. LMNA mutation position predicts organ system involvement in laminopathies. Clin Genet. 2005;68(1):31\u20134.","journal-title":"Clin Genet"},{"issue":"7","key":"5886_CR9","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1194\/jlr.R700004-JLR200","volume":"48","author":"RA Hegele","year":"2007","unstructured":"Hegele RA, Joy TR, Al-Attar SA, Rutt BK. Thematic review series: adipocyte biology. Lipodystrophies: windows on adipose biology and metabolism. J Lipid Res. 2007;48(7):1433\u201344.","journal-title":"J Lipid Res"},{"key":"5886_CR10","doi-asserted-by":"crossref","unstructured":"Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Ryd\u00e9n L, Marx N, Brosius FC 3rd, Mustafa RA, Agarwal A, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023;381.","DOI":"10.1136\/bmj-2022-074068"},{"key":"5886_CR11","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, Yuan CS. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410.","journal-title":"BMJ"},{"issue":"7","key":"5886_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJMoa1903822","volume":"381","author":"WV Tamborlane","year":"2019","unstructured":"Tamborlane WV, Barrientos-P\u00e9rez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch JL, et al. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019;381(7):637\u201346.","journal-title":"N Engl J Med"},{"issue":"4","key":"5886_CR13","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1086\/302836","volume":"66","author":"RA Speckman","year":"2000","unstructured":"Speckman RA, Garg A, Du F, Bennett L, Veile R, Arioglu E, Taylor SI, Lovett M, Bowcock AM. Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A\/C. Am J Hum Genet. 2000;66(4):1192\u20138.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"5886_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/72807","volume":"24","author":"S Shackleton","year":"2000","unstructured":"Shackleton S, Lloyd DJ, Jackson SN, Evans R, Niermeijer MF, Singh BM, Schmidt H, Brabant G, Kumar S, Durrington PN, et al. LMNA, encoding lamin A\/C, is mutated in partial lipodystrophy. Nat Genet. 2000;24(2):153\u20136.","journal-title":"Nat Genet"},{"issue":"2","key":"5886_CR15","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.4158\/ACCR-2019-0366","volume":"6","author":"NXS de Andrade","year":"2020","unstructured":"de Andrade NXS, Adiyaman SC, Yuksel BD, Ferrari CT, Eldin AJ, Saydam BO, Altay C, Sharma P, Bhave N, Little A, et al. Unusual presentations of LMNA-associated lipodystrophy with complex phenotypes and generalized fat loss: when the genetic diagnosis uncovers novel features. AACE Clin Case Rep. 2020;6(2):e79-85.","journal-title":"AACE Clin Case Rep"},{"key":"5886_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.metabol.2017.04.010","volume":"72","author":"B Akinci","year":"2017","unstructured":"Akinci B, Onay H, Demir T, Savas-Erdeve \u015e, Gen R, Simsir IY, Keskin FE, Erturk MS, Uzum AK, Yaylali GF, et al. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy. Metabolism. 2017;72:109\u201319.","journal-title":"Metabolism"},{"issue":"4","key":"5886_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5603\/EP.2013.0010","volume":"64","author":"K Nabrdalik","year":"2013","unstructured":"Nabrdalik K, Str\u00f3zik A, Minkina-P\u0119dras M, Jarosz-Chobot P, M\u0142ynarski W, Grzeszczak W, Gumprecht J. Dunnigan-type familial partial lipodystrophy associated with the heterozygous R482W mutation in LMNA gene - case study of three women from one family. Endokrynol Pol. 2013;64(4):306\u201311.","journal-title":"Endokrynol Pol"},{"issue":"3","key":"5886_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0028-3843(14)60044-X","volume":"44","author":"H Drac","year":"2010","unstructured":"Drac H, Madej-Pilarczyk A, Gospodarczyk-Szot K, Gawe\u0142 M, Kwieci\u0144ski H, Hausmanowa-Petrusewicz I. Familial partial lipodystrophy associated with the heterozygous LMNA mutation 1445G > a (Arg482Gln) in a Polish family. Neurol Neurochir Pol. 2010;44(3):291\u20136.","journal-title":"Neurol Neurochir Pol"},{"issue":"2","key":"5886_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2022.101409","volume":"49","author":"G Treiber","year":"2023","unstructured":"Treiber G, Guilleux A, Huynh K, Bonfanti O, Flaus-Furmaniuk A, Couret D, Mellet N, Bernard C, Le-Moullec N, Doray B, et al. Lipoatrophic diabetes in familial partial lipodystrophy type 2: from insulin resistance to diabetes. Diabetes Metab. 2023;49(2): 101409.","journal-title":"Diabetes Metab"},{"issue":"4","key":"5886_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1055\/s-0031-1301284","volume":"44","author":"A Luedtke","year":"2012","unstructured":"Luedtke A, Boschmann M, Colpe C, Engeli S, Adams F, Birkenfeld AL, Haufe S, Rahn G, Luft FC, Schmidt HH, Jordan J. Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: a case series. Horm Metab Res. 2012;44(4):306\u201311.","journal-title":"Horm Metab Res"},{"key":"5886_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13098-017-0226-0","volume":"9","author":"CM Valerio","year":"2017","unstructured":"Valerio CM, de Almeida JS, Moreira RO, Aguiar LBS, Siciliano PO, Carvalho DP, Godoy-Matos AF. Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2. Diabetol Metab Syndr. 2017;9:26.","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"5886_CR22","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356.","journal-title":"Cell Metab"},{"issue":"4","key":"5886_CR23","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2337\/dc23-1614","volume":"47","author":"MC Foss-Freitas","year":"2024","unstructured":"Foss-Freitas MC, Imam S, Neidert A, Gomes AD, Broome DT, Oral EA. Efficacy and safety of Glucagon-like peptide 1 agonists in a retrospective study of patients with familial partial lipodystrophy. Diabetes Care. 2024;47(4):653\u20139.","journal-title":"Diabetes Care"},{"issue":"9","key":"5886_CR24","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/dom.12926","volume":"19","author":"M Monami","year":"2017","unstructured":"Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, Mannucci E. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes Obes Metab. 2017;19(9):1233\u201341.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"5886_CR25","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","volume":"16","author":"EA Oral","year":"2022","unstructured":"Oral EA, Garg A, Tami J, Huang EA, O\u2019Dea LSL, Schmidt H, Tiulpakov A, Mertens A, Alexander VJ, Watts L, et al. Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with Familial partial lipodystrophy: results of the BROADEN study: volanesorsen in FPLD; the BROADEN study. J Clin Lipidol. 2022;16(6):833\u201349.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"5886_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12944-021-01589-4","volume":"20","author":"MC Foss-Freitas","year":"2021","unstructured":"Foss-Freitas MC, Akinci B, Neidert A, Bartlett VJ, Hurh E, Karwatowska-Prokopczuk E, Oral EA. Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study. Lipids Health Dis. 2021;20(1):174.","journal-title":"Lipids Health Dis"},{"issue":"8","key":"5886_CR27","doi-asserted-by":"publisher","first-page":"e2953","DOI":"10.1210\/clinem\/dgab216","volume":"106","author":"K Cook","year":"2021","unstructured":"Cook K, Ali O, Akinci B, Foss de Freitas MC, Montenegro RM, Fernandes VO, Gupta D, Lou KJ, Tuttle E, Oral EA, Brown RJ. Effect of leptin therapy on survival in generalized and partial lipodystrophy: A matched cohort analysis. J Clin Endocrinol Metab. 2021;106(8):e2953\u201367.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05886-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-025-05886-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05886-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T01:06:16Z","timestamp":1751850376000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-025-05886-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5886"],"URL":"https:\/\/doi.org\/10.1186\/s12887-025-05886-0","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was in compliance with the Helsinki Declaration and was approved by the Ethical Review Board of Shanghai Children\u2019s Hospital (clinical trial number: not applicable). Written informed consent to participate in this study was provided by the participants and legal guardian of kin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consents were obtained from the parents and the participants for the publication of this study. The parents and the participants consented to the publication of the case and any accompanying images with written consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"537"}}